Search this website

About ▼ Research ▼ Patient & Public Involvement ▼ Training Hub ▼ Industry ▼ Videos News Events

### News

You are here: Home > COVID-19 > Second study confirms benefits of budesonide in early stages of COVID-19

# Second study confirms benefits of budesonide in early stages of COVID-19

12 August 2021 · Listed under COVID-19, Respiratory

A UK-

#### **NEWS**

University of Oxford Announces Opening of PanDox Phase 1 Study investigating Targeted Drug Delivery by Focused Ultrasound for Pancreatic Cancer 21 October 2021


Largest ever global study of tuberculosis identifies genetic causes of drug resistance

19 October 2021

Black History Month talk explores health inequalities

19 October 2021





wide clinical study has confirmed the findings of an earlier Oxford BRC-supported study showing that the early treatment with the inhaled asthma medication budesonide speeds up recovery from COVID-19 and reduces the risk of hospitalisation and death.

The latest study – part of the <u>PRINCIPLE trial</u>, which is looking at potential treatments for COVID-19 in the community with the aim of preventing hospitalisation – found that inhaled budesonide improves time to recovery, with a chance of also reducing hospital admissions or deaths.

The findings, published in <u>the Lancet</u>, support the earlier results of the <u>STOIC</u> <u>trial</u>, which was led by BRC-supported researcher Professor Mona Bafadhel, who was also one of the co-authors on the PRINCIPLE Trial study.

This latest randomised study found that Inhaled budesonide improved time to recovery, with a chance of also reducing hospital admissions or deaths in people with COVID-19 in the community who are at higher risk of complications.

The 4,700 participants were aged 65 years or older or 50 years or older with comorbidities, and unwell for up to 14 days with suspected COVID-19 but not admitted to hospital.

Commenting on twitter, Prof Bafadhel said: "Very proud to have worked with [the Principle Trial] getting this trial done. Inhaled <u>budesonide</u> in high risk populations with early <u>COVID-19</u> quickened recovery of symptoms and reduced risk of hospitalisation/death. This trial replicates the Phase 2 STOIC trial findings ...

Another weapon in the battle against <u>COVID-19</u>. This one affordable and available worldwide now.

← BRC-supported study receives Best Research Paper Award

Vaccination still best protection, but less effective against Delta variant, study finds  $\rightarrow$ 

## Subscribe to the Oxford BRC Newsletter

Keep informed about the work of the Oxford BRC by subscribing to our Mailchimp e-newsletter. It is produced bimonthly and delivers news and information about upcoming events straight to your inbox.

Subscribe Now

#### Get Involved

Active involvement in clinical research at our centre in Oxford may give you the opportunity to have a say in how the research is carried out or to comment on research in an area that has affected you, your family or friends. Whatever time you can spare, or whatever your interests are in the work at our Research Centre, do please take a moment to fill in the 'Get involved' form and we will contact you shortly.

#### Oxford BRC on Social Media



#### Feedback

We'd love to hear your feedback. Please contact us at obrcenquiries@ouh.nhs.uk

Sitemap Data Control and Privacy Accessibility Our Partners Disclaimer Contact

Copyright © 2021 NIHR Oxford Biomedical Research Centre

#### **Cookies**

This site uses cookies See our data control and privacy page

Dismiss this notice